所有图片(1)

文件

SML3317

Losartan

Name: Losartan
Brand: SIGMA

≥98% (HPLC), powder, angiotensin II receptor type 1 (AT1) antagonist

别名:

1-[1-[[2′-(2H-Tetrazol-5-yl)biphenyl-4-yl]methyl]-2-butyl-4-chloro-1H-imidazol-5-yl]methanol, 2-Butyl-4-chloro-1-[[2′-(1H-tetrazol-5-yl)-1,1′-biphenyl-4-yl]methyl]-1H-imidazole-5-methanol, 2-Butyl-4-chloro-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol, DUP 89

登录查看公司和协议定价

所有图片(1)

About This Item

经验公式（希尔记法）:

C₂₂H₂₃ClN₆O

CAS号:

114798-26-4

分子量:

422.91

MDL编号:

MFCD19686114

UNSPSC代码:

12352200

NACRES:

NA.77

product name

Losartan, ≥98% (HPLC)

质量水平

100

检测方案

≥98% (HPLC)

形式

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=C(C4=NNN=N4)C=CC=C3)C=C2

InChI

1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)

InChI key

PSIFNNKUMBGKDQ-UHFFFAOYSA-N

正在寻找类似产品? 访问产品对比指南

生化/生理作用

Losartan is an orally available, potent, and selective competitive angiotensin II receptor type 1 (AT1) antagonist. Losartan is used for treatment of hypertension.

象形图

GHS08,GHS07

警示用语：

Danger

危险声明

H317,H360FD,H362

预防措施声明

P202 - P260 - P263 - P280 - P302 + P352 - P308 + P313

危险分类

Lact. - Repr. 1B - Skin Sens. 1

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2).

P C Wong et al.

The Journal of pharmacology and experimental therapeutics, 255(2), 584-592 (1990-11-01)

DuP 753 and PD123177 are two nonpeptide angiotensin II (AII)-specific ligands, which show high affinities for two respective and distinct subtypes of AII binding sites, i.e., AII-1 and AII-2 sites, respectively, in the rat adrenal gland, brain and uterus. The

Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma.

Daniel P Regan et al.

Clinical cancer research : an official journal of the American Association for Cancer Research, 28(4), 662-676 (2021-09-29)

There is increasing recognition that progress in immuno-oncology could be accelerated by evaluating immune-based therapies in dogs with spontaneous cancers. Osteosarcoma (OS) is one tumor for which limited clinical benefit has been observed with the use of immune checkpoint inhibitors.

Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis.

Yoon-A Park et al.

Journal of personalized medicine, 11(7) (2021-07-03)

This study aimed to investigate the influence of CYP2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite, E-3174, through a systematic review and meta-analysis. Eight studies published before March 2021 were included in this study. We used

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件